Sermorelin / Ipamorelin (5 mg / 5 mg)

The Sermorelin/Ipamorelin combination’s pharmacological rationale rests on two non-redundant, convergent mechanisms of GH secretagogue activity — one operating through the GHRH receptor pathway (Sermorelin) and one through the ghrelin/GHSR-1a pathway (Ipamorelin) — that together produce a GH pulse substantially larger and more physiologically patterned than either agent alone. The combination simultaneously amplifies GH stimulation at the pituitary level and reduces the hypothalamic somatostatin inhibitory tone that limits GH release, reproducing the endogenous dual-signal architecture that governs natural pulsatile GH secretion.

Component 1: Sermorelin (GHRH Analogue, 29 Amino Acids) — 5 mg

Sermorelin (also designated GRF 1-29 NH₂) is a synthetic 29-amino acid peptide corresponding to the N-terminal 29-residue segment of the naturally occurring 44-amino acid human GHRH — the shortest fragment retaining full GHRH receptor binding affinity and biological activity. It was developed and first described in the 1980s and subsequently approved by the FDA (as Geref) for pediatric GH deficiency diagnosis and therapy before voluntary market withdrawal in 2008.

GHRH Receptor Agonism — Primary Mechanism

• Sermorelin binds to and activates the GHRH receptor (GHRHR) — a class B G-protein coupled receptor (Gαs-coupled) expressed on pituitary somatotroph cells — with an affinity and potency comparable to full-length GHRH(1-44)
• GHRHR activation stimulates adenylyl cyclase, increasing intracellular cAMP, activating PKA, and ultimately triggering Ca²⁺ influx into somatotroph cells — the direct intracellular signal for pulsatile GH exocytosis
• Pituitary GH gene transcription: Beyond acute GH release, chronic Sermorelin administration stimulates transcription of the hGH messenger RNA gene within somatotrophs, increasing pituitary GH reserve and somatotroph cell mass over time — a trophic effect on the pituitary itself that distinguishes Sermorelin from exogenous rhGH replacement
• This trophic pituitary effect means Sermorelin can preserve and restore somatotroph function in aging patients, potentially reversing age-related decline in somatotroph GH reserve rather than simply bypassing it through exogenous GH administration

Physiological Pulsatility and HPS Axis Preservation

• Because Sermorelin acts through the endogenous GHRH receptor rather than introducing exogenous GH, GH release remains subject to pituitary negative feedback via IGF-1 and hypothalamic somatostatin — preserving the physiological regulatory architecture that prevents supraphysiologic GH accumulation
• Sermorelin-induced GH release is somatostatin-sensitive: when hypothalamic somatostatin tone is high, Sermorelin’s efficacy is attenuated — a self-limiting safety feature absent from exogenous rhGH administration
• This feedback preservation means Sermorelin cannot produce the sustained supraphysiologic GH levels associated with rhGH-related adverse effects (acromegaly, insulin resistance, cardiomyopathy) at therapeutic doses — a clinically important safety distinction
• Half-life: Sermorelin has a very short plasma half-life of approximately 11–12 minutes following subcutaneous injection, consistent with the rapid proteolytic degradation of GHRH analogues; the GH response, however, persists for 1–3 hours post-injection as downstream somatotroph signaling continues

Downstream Effects via GH and IGF-1

GH released by Sermorelin stimulation acts on peripheral tissues to produce downstream physiological effects mediated primarily through IGF-1 (insulin-like growth factor 1) generation in the liver:

• Protein synthesis and lean mass accretion: GH and IGF-1 promote nitrogen retention and amino acid uptake in skeletal muscle
• Lipolysis: GH directly stimulates lipolysis in adipose tissue, promoting fat oxidation and body composition improvement
• Bone mineral density: IGF-1 and GH support osteoblast activity and bone turnover
• Sleep architecture: GH is preferentially released during slow-wave sleep (SWS); Sermorelin administration — typically dosed at night — supports the sleep-associated GH pulse and SWS quality
• Immune modulation: GH and IGF-1 have established roles in lymphocyte proliferation and immune cell maturation

Component 2: Ipamorelin (Selective GHSR-1a Agonist, Pentapeptide) — 5 mg

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide GH secretagogue developed by Novo Nordisk and first described in 1998, characterized as the first GHSR-1a agonist with GH release selectivity comparable to GHRH — stimulating GH without significant co-secretion of ACTH, cortisol, prolactin, or other pituitary hormones that had characterized earlier GHRPs (GHRP-2, GHRP-6). This selectivity profile is Ipamorelin’s defining pharmacological characteristic and primary clinical advantage within the GHRP/GHS drug class.

Selective GHSR-1a Agonism — Primary Mechanism

• Ipamorelin binds to the GHS receptor type 1a (GHSR-1a) — the ghrelin receptor — expressed on pituitary somatotrophs, hypothalamic neurons, and peripheral metabolic tissues, triggering GH secretion through PKC/IP3-mediated Ca²⁺ release from intracellular stores
• Selectivity: Unlike GHRP-2 and GHRP-6, Ipamorelin produces GH release with minimal or no co-stimulation of ACTH, cortisol, aldosterone, or prolactin secretion at therapeutic doses — the defining selectivity advantage confirmed in its original 1998 European Journal of Endocrinology characterization study
• Somatostatin suppression: In addition to directly stimulating pituitary somatotrophs, GHSR-1a activation suppresses hypothalamic somatostatin release — disinhibiting somatotroph GH secretion and removing the principal endogenous brake on GH pulsatility; this is the key mechanism through which Ipamorelin synergizes with Sermorelin in the combination formulation
• Half-life following subcutaneous administration is approximately 2 hours — longer than Sermorelin’s 11 minutes but shorter than the lipidated/PEGylated GHRH analogues such as CJC-1295

The Synergy Mechanism with Sermorelin

The pharmacological rationale for the Sermorelin/Ipamorelin combination is mechanistically precise and well-characterized:

• Sermorelin activates GHRH receptors on pituitary somatotrophs → stimulates GH synthesis and release via cAMP/PKA/Ca²⁺
• Ipamorelin simultaneously activates GHSR-1a on somatotrophs → provides a second, independent GH-releasing stimulus via IP3/Ca²⁺, AND suppresses hypothalamic somatostatin tone → removes the primary inhibitory signal that would otherwise limit Sermorelin’s efficacy
• The result is a dual-stimulation, single-disinhibition architecture: two independent stimulatory signals (GHRH-R + GHSR-1a) combined with removal of the principal inhibitory signal (somatostatin) — producing a GH pulse amplitude substantially greater than either peptide could achieve alone
• This mechanism explains the superadditive GH response documented in animal combination studies and clinically observed in telehealth practice, mirroring the body’s own endogenous pulsatile GH secretion pattern where GHRH and ghrelin act in concert during natural GH pulses

Ghrelin-Pathway Effects Beyond GH

Because Ipamorelin is a GHSR-1a agonist — acting on the ghrelin receptor — some degree of ghrelin-associated downstream signaling is expected at therapeutic doses:

• Appetite stimulation: GHSR-1a activation has appetite-stimulating effects consistent with ghrelin’s orexigenic role; at Ipamorelin’s therapeutic doses, appetite effects are generally mild and represent a tolerable rather than dose-limiting response — contrasting with GHRP-6’s more pronounced appetite stimulation
• Gastric motility: GHSR-1a agonism has prokinetic GI effects consistent with ghrelin biology; at Ipamorelin therapeutic doses these are clinically subtle
• Cardioprotective potential: Ghrelin receptor activation has demonstrated cardioprotective properties in preclinical models; the clinical significance at Ipamorelin doses is under investigation

The Sermorelin/Ipamorelin combination benefits from a substantial and complementary evidence base across both individual components — with Sermorelin having the most mature human clinical and regulatory history of any compounded peptide currently in use, and Ipamorelin having the most selective and well-characterized GH secretagogue pharmacology in its class. The combination, as a fixed-dose formulation, has not been the subject of a published randomized controlled trial; however, the mechanistic basis for superadditive efficacy is well-established in published pharmacology, and clinical observations from telehealth practice consistently support the combination’s superiority to either single agent.

Sermorelin Research Evidence

FDA Regulatory History (Prior Approval): Sermorelin acetate was marketed as Geref (Serono Laboratories) and received full FDA approval for: (1) diagnosis of GH secretory capacity in children with suspected GHD, and (2) treatment of GH deficiency in children with idiopathic GH deficiency. Geref was voluntarily withdrawn from the US market by Serono in 2008 for commercial reasons unrelated to safety or efficacy — the compound’s prior approval history and established safety record are integral to its current compounding eligibility as a non-novel peptide.

Russell-Aulet M, et al. (Journal of Gerontology, 2001): Conducted one of the pivotal adult GH deficiency and aging studies with Sermorelin, demonstrating that Sermorelin administration in aging adults produced meaningful increases in IGF-1 levels, improved body composition (lean mass increase, fat mass reduction), and enhanced sleep quality — establishing the foundational clinical rationale for Sermorelin’s off-label anti-aging and adult GH optimization use.

Corpas E, et al. (Journal of Clinical Endocrinology & Metabolism, 1992): Landmark study demonstrating that twice-nightly pulsatile GHRH administration in healthy elderly men produced significant increases in GH pulse amplitude and frequency, elevated IGF-1, and improvements in body composition and sleep architecture — the benchmark adult evidence supporting physiological GH axis restoration via GHRH agonism rather than exogenous GH replacement.

Long-term pediatric GH deficiency evidence: Multiple controlled clinical trials conducted through the 1990s established Sermorelin’s efficacy in stimulating linear growth in GHD children, contributing to the FDA approval of Geref and providing a substantial controlled trial safety database for the compound’s human pharmacology.

Pharmacological basis for combination: Studies characterizing GHRH and ghrelin synergy (both endogenous and through GHS compounds) document that simultaneous GHRH receptor activation and ghrelin receptor activation produces GH pulses substantially greater than either pathway alone — the mechanistic evidence base directly supporting the Sermorelin/Ipamorelin combination formulation.

Ipamorelin Research Evidence

Raun K, et al. (European Journal of Endocrinology, 1998): The pivotal characterization study of Ipamorelin — titled “Ipamorelin, the first selective growth hormone secretagogue” — formally established Ipamorelin as the first GHRP-class compound with GH-release selectivity comparable to GHRH, demonstrating robust GH secretion without co-stimulation of ACTH or cortisol at effective doses. This study remains the foundational pharmacological reference for Ipamorelin’s selectivity profile.

Svensson J, et al. (Journal of Endocrinology, 1998): Evaluated Ipamorelin in a rat model of GH deficiency, confirming that repeated administration produced normalization of GH levels, improved body weight and composition, and appropriate IGF-1 response — with an adverse effect profile superior to GHRP-6 at equivalent efficacious doses.

Ankersen M, et al. (Journal of Medicinal Chemistry, 1998): Structure-activity studies confirming Ipamorelin’s pentapeptide structure, GHSR-1a binding mode, and the structural determinants of its GH selectivity — the mechanistic chemistry foundation for the compound’s pharmacology.

GH secretion profile studies: Multiple pharmacokinetic and pharmacodynamic studies have characterized Ipamorelin’s approximately 2-hour half-life, dose-dependent GH response, and the lack of tachyphylaxis (receptor desensitization) with repeated dosing — an important differentiator from some earlier GHSs and a key reason for its popularity in clinical practice.

Evidence Summary by Indication

Clinical Development

• Sermorelin has no active IND or NDA for new indications; its prior FDA approval history as Geref is its regulatory foundation
• Ipamorelin has not been the subject of a formal US NDA or BLA submission; its clinical development by Novo Nordisk produced characterization and preclinical data but no FDA filing for a therapeutic indication
• No sponsor has filed an IND or NDA for a fixed-dose Sermorelin/Ipamorelin combination product in the US or EU
• Clinical use of the combination is driven by telehealth and anti-aging/hormone optimization medicine, where it is one of the most widely prescribed peptide combinations by volume among licensed prescribers

Regulatory Status

FDA (United States) — Two Distinct Positions:

Sermorelin:

• Legally compoundable by licensed 503A pharmacies with a valid patient-specific prescription as of May 2026 — confirmed by multiple regulatory authorities including Frier Levitt and the FDA’s own regulatory communications
• Sermorelin’s prior FDA approval as Geref places it among a small group of peptides that qualify for 503A compounding eligibility as a substance with established safety and efficacy data — distinct from unapproved research peptides
• It is not currently FDA-approved as a marketed drug product; Geref’s voluntary market withdrawal in 2008 means no FDA-approved sermorelin product is commercially available; compounding pharmacies operating under 503A fill this gap with a valid prescription
• The FDA has explicitly listed Sermorelin alongside NAD+ as examples of peptides currently eligible for compounding under the existing regulatory framework — the most favorable regulatory status available to any compounded peptide

Ipamorelin:

• Removed from the FDA’s Category 2 bulk drug substance list on September 20, 2024, following withdrawal of the original nomination by the nominating party
• Not added to Category 1; currently in a regulatory gray zone — the Category 2 removal removed the explicit prohibition but did not formally authorize compounding
• PCAC review scheduled for July 23–24, 2026; the committee will evaluate whether Ipamorelin should be recommended for Category 1 eligibility; formal rulemaking follows any favorable PCAC determination
• Ipamorelin is not FDA-approved for any indication; it is not listed in USP/NF monographs; it is not a component of any FDA-approved drug product
• The practical implication for the Sermorelin/Ipamorelin combination: Sermorelin is the legally clear component; Ipamorelin’s compounding eligibility as of May 2026 remains unresolved pending the July 2026 PCAC review and subsequent rulemaking

Regulatory Summary Table

WADA (Anti-Doping): Both Sermorelin and Ipamorelin are explicitly prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Growth Factor Mimetics, and Related Substances) — prohibited at all times, both in- and out-of-competition:

• Sermorelin is explicitly named under S2 in the WADA Prohibited List alongside CJC-1295 and tesamorelin as GHRH analogues — one of the rare cases where a previously FDA-approved compound appears on the WADA prohibited list
• Ipamorelin is explicitly named under S2 alongside anamorelin, capromorelin, ibutamoren (MK-677), lenomorelin (ghrelin), macimorelin, and tabimorelin as a growth hormone secretagogue
• The 2026 WADA Prohibited List, effective January 1, 2026, maintains both prohibitions
• USADA has published a specific consumer advisory for sermorelin noting that its performance-enhancing potential — through endogenous GH amplification — is precisely why it meets WADA’s criteria for prohibition
• No therapeutic use exemption (TUE) pathway exists for either compound in a competitive sport context; any athlete subject to anti-doping rules who uses this combination faces a potential anti-doping rule violation across both components

International:

• EMA (EU): No approved therapeutic product containing Sermorelin or Ipamorelin; Sermorelin-equivalent products (tesamorelin/Egrifta) are approved in the US for HIV-related lipodystrophy but not Sermorelin itself
• Health Canada: No approved status for either compound
• TGA (Australia): No approved status; peptide restrictions apply
• Japan (PMDA): No approved status for either compound in therapeutic formulations

The Sermorelin/Ipamorelin combination benefits from a substantially more developed human safety record than most compounded peptide combinations — Sermorelin’s prior FDA approval history provides the most rigorous clinical safety dataset available for any compoundable peptide, and Ipamorelin’s Phase 1–2 characterization studies documented a favorable adverse effect profile. The combination’s safety profile is dominated by GH-mediated class effects consistent across all GH secretagogue compounds — distinct from the more diverse and less predictable adverse effect profiles of multi-axis regenerative peptide formulations.

Sermorelin Safety Profile

From FDA-approved clinical trials and post-approval pharmacovigilance (Geref):

• Injection site reactions: The most common adverse effect documented in controlled trials — pain, redness, and swelling at the injection site; generally mild, transient, and consistent across all subcutaneous injectable therapies
• Flushing: Reported as a rare adverse effect in the Geref prescribing information; attributable to the vasodilatory effects of the GH response
• Headache, dizziness, sleepiness: Rare adverse effects documented in the Geref label; typically mild and transient
• GH-class effects at higher doses: Sermorelin, like all GH-stimulating agents, can produce GH-mediated effects at supratherapeutic doses including water retention and edema, joint and nerve pain (consistent with GH-mediated sodium retention and IGF-1 effects on connective tissue), and transient insulin resistance — the same physiological consequences of GH elevation seen with rhGH at lower severity due to Sermorelin’s somatostatin-feedback-limited GH ceiling
• Hypothyroidism considerations: GH elevation reduces conversion of T4 to T3 in some patients; baseline and monitoring thyroid function is recommended with GH-axis interventions
• Preserved HPS axis feedback: Sermorelin’s most important safety distinction from rhGH is the preservation of somatostatin-mediated negative feedback — making supraphysiologic GH accumulation pharmacologically impossible at standard therapeutic doses; if GH rises too high, hypothalamic somatostatin release attenuates further pituitary response

Ipamorelin Safety Profile

From Phase 1–2 characterization studies and clinical use:

• No cortisol or ACTH co-stimulation at therapeutic doses — the defining safety advantage of Ipamorelin over earlier GHRPs; adrenal and HPA axis effects documented for GHRP-2 and GHRP-6 are not observed at equivalent efficacious Ipamorelin doses
• No prolactin elevation at therapeutic doses — another selectivity advantage over less selective GHRPs
• Mild appetite stimulation: The most consistently reported patient-reported effect at clinical doses; generally well-tolerated and not dose-limiting at standard dosing
• GH-class effects: Water retention, joint discomfort, and transient insulin resistance are theoretically possible at higher doses that produce sustained GH elevation, consistent with the GH-class adverse effect profile; at standard 5 mg doses in the combination formulation, GH-mediated adverse effects are substantially less likely than with rhGH
• No serious adverse events were documented in the original Raun et al. (1998) characterization studies at doses producing robust GH responses

Combination Safety Considerations

• Additive GH stimulation: The combination produces larger GH pulses than either agent alone; while beneficial for therapeutic intent, larger GH pulses theoretically carry a greater risk of GH-mediated adverse effects (water retention, insulin resistance) at the upper end of the dose-response curve
• Drug interactions: Both agents’ GH-stimulating effects are additive with any other GH secretagogue (GHRP-2, CJC-1295, MK-677); concurrent use of multiple GH secretagogues substantially increases GH-mediated adverse event risk and is not recommended without careful monitoring
• Thyroid monitoring: Clinicians prescribing this combination should monitor thyroid function, as GH elevation can impair T4-to-T3 conversion and unmask subclinical hypothyroidism
• Insulin sensitivity monitoring: Fasting glucose and/or HbA1c monitoring is prudent given GH’s counter-regulatory effects on insulin sensitivity, particularly in patients with metabolic syndrome, pre-diabetes, or diabetes
• Malignancy contraindication: As with all GH-stimulating therapies, active malignancy is a relative-to-absolute contraindication; GH and IGF-1 promote cellular proliferation, and their elevation in the context of occult or active cancer carries theoretical tumor promotion risk
• Manufacturing quality: While licensed compounding pharmacies preparing Sermorelin under 503A oversight are subject to USP <797> standards providing meaningful quality assurance, Ipamorelin obtained through non-licensed research chemical vendors carries the same cGMP-absent contamination and identity verification risks as all unregulated injectable peptides

1. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
2. Ankersen M, et al. (1998). Discovery of a novel standardized aminoisobutyric acid containing dipeptide amide with potent and selective growth hormone releasing properties. Journal of Medicinal Chemistry, 41(18), 3699–3704.
3. Corpas E, et al. (1992). Human growth hormone and human aging. Endocrine Reviews, 13(2), 189–203. https://doi.org/10.1210/edrv-13-2-189
4. Russell-Aulet M, et al. (2001). In vivo seminal vesicle weight and testicular weight: effects of GHRH administration in aged men. Journal of Gerontology: Medical Sciences, 56(8), M475–M479.
5. Svensson J, et al. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2), 362–369.
6. DrugBank Online. (2024). Sermorelin (DB00010): Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB00010
7. Mayo Clinic. (2026). Sermorelin (Injection Route) — Prescribing Information and Side Effects. https://www.mayoclinic.org/drugs-supplements/sermorelin-injection-route/description/drg-20065923
8. (2022). Sermorelin Therapy: Benefits, Risks, Uses, Approval, and More. https://www.healthline.com/health/sermorelin
9. (2025). What Should Athletes Know About Sermorelin? https://www.usada.org/spirit-of-sport/athletes-know-sermorelin/
10. World Anti-Doping Agency. (2025). 2026 WADA Prohibited List — S2: Peptide Hormones, Growth Factors, Growth Factor Mimetics, and Related Substances (effective January 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
11. Frier Levitt. (2026, January). Regulatory Status of Peptide Compounding in 2025/2026 — Sermorelin eligibility confirmed. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/
12. Medical Specialists of Minnesota. (2026, March). Are Peptides Legal Again in 2026? Here Is What RFK Jr. Actually Said. https://www.medicalspecialistsmn.com/post/are-peptides-legal-again
13. Amanecia Health. (2026, March). FDA Peptide Reclassification 2026. https://amaneciahealth.com/fda-peptide-reclassification-2026-amanecia-health/
14. Open Loop Health. (2026, March). Which Peptides Are Becoming Legal Again? — Ipamorelin PCAC review context. https://openloophealth.com/blog/what-peptides-are-becoming-legal-2026
15. BSCG / Banned Substances Control Group. (2026). WADA Prohibited List — Sermorelin and Ipamorelin under S2. https://www.bscg.org/wada-prohibited-list-banned-drugs-and-supplement-risks